By Justin Petrone

Premature obituaries and conflicting narratives. Funding constraints and flurries of new product launches. At times over the past year it seemed that array makers themselves didn't know what would happen next in the market, and as 2012 dawns, that appears to still be the case.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.